Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT)
Status:
Unknown status
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Patients with proliferative diabetic retinopathy requiring surgical intervention will receive
a pre-operative injection of Conbercept. Patients will be recruited into different groups
according to variable time intervals (1 to 7 days) between intravitreous injection and
surgery. At initial, pre-injection aqueous humor and blood sample will be collected in order
to provide baseline VEGF-A, -B, placental growth factor (PIGF), and other cytokine levels. At
the onset of the vitrectomy, a second aqueous humor, blood, and vitreous sample will be taken
to obtain intra-operative levels of , VEGF-A, -B, PIGF, and other cytokine levels.
Phase:
Phase 4
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University